Perforomist FDA Approval History
FDA Approved: Yes (First approved May 11, 2007)
Brand name: Perforomist
Generic name: formoterol fumarate
Dosage form: Inhalation Solution
Company: Dey, L.P.
Treatment for: COPD
Perforomist is an inhalation solution formulation of the long-acting beta(2)-adrenergic agonist formoterol fumarate, indicated for the long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
Development timeline for Perforomist
| Date | Article |
|---|---|
| May 11, 2007 | Approval FDA Approves Dey, L.P.'s Perforomist (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
